Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for December 2009
December 1, 2009
- Lorus Therapeutics Announces Positive Result in Its Phase II Clinical Study of LOR-2040 in Acute Myeloid Leukemia (AML)
- Tripep: The ChronVac-C Study Has Been Successfully Completed with Good Safety and Favorable Clinical Data
- OxyPharma Announces Positive Results of a Double-Blind, Placebo-Controlled Phase II Trial of Three Dosage Levels of Rabeximod Versus Placebo in Patients with Rheumatoid Arthritis
- Velcade (Bortezomib) for Injection to be Featured in Plenary Session at American Society of Hematology
- Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
December 2, 2009
- Sepracor to Present New STEDESA Clinical Data at American Epilepsy Society Annual Meeting
- ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
- Biofrontera AG (DE) - Ad hoc: Phase III data of BF-200 ALA demonstrate superiority against Metvix
- Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoints in Head-to-Head Study with Sitagliptin (Januvia) and versus Placebo
- Spectrum Pharmaceuticals Announces ZEVALIN Data Presentations at the 51st Annual Meeting of the American Society of Hematology in New Orleans
- Provectus Announces Preliminary Phase 2 Data For PH-10 in its Psoriasis and Atopic Dermatitis Trials
- Acceleron Pharma to Present Data on ACE-011 and ACE-536 at the 51st Annual Meeting of the American Society of Hematology
- Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at ASH 2009 Annual Meeting
- ImmunoCellular Therapeutics to Present at LD Micro Conference on December 3rd
- Calistoga Pharmaceuticals Announces Two Oral Presentations on CAL-101 at 51st American Society of Hematology (ASH) Annual Meeting
- Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and Exposition
- ChemGenex to Present Positive Data for Omapro From Multiple Clinical Trials at ASH
December 3, 2009
- Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses When the Vaccine is Delivered by Electrical Impulses
- ChemGenex to Present Positive Data for Omapro from Multiple Clinical Trials
- NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
- S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
- Alizé Pharma reveals promising data on Asparec program for second-line ALL therapy
December 4, 2009
- The International Myeloma Foundation Says for the First Time Medical Conference Presentations Will Cover Treating All Stages of Myeloma
- Study Finds Generex Oral-lyn Is Safe, Effective, May Reduce Complications Of Insulin-dependent Diabetes
- Pharmaxis Announces Sustained Benefit With Bronchitol In Phase 3 Cystic Fibrosis Trial
- The Female Patient Launches Digital Edition: Press Release for Immediate Distribution
- PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
- Degarelix (FIRMAGON) vs Leuprolide (Lupron Depot) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
- New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C
- Webinar to Explore FDA Draft REMS Guidance and Its Implications for Lifecycle Management
- Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211
December 7, 2009
- Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma
- New STEDESA Clinical Data Presented at American Epilepsy Society Annual Meeting in Boston
- Canadian co-led, global trial shows dabigatran etexilate as effective as well controlled warfarin, with less bleeding, in treatment of acute venous thromboembolism
- Phase III EINSTEIN-Extension Study of Bayer ?s Rivaroxaban Shows Significant Benefit in the Prevention of Secondary Symptomatic VTE
- AS1413 regimen yields high response rate and durable responses in patients with secondary AML, a poor-risk population underserved by current treatment options
- "Immunoconjugate BT-062 shows first data of clinical efficacy"
- Carfilzomib Data Demonstrate Promising Efficacy and Tolerability Signals in Ongoing Phase 1b/2 Combination Study
- Carfilzomib Demonstrates Encouraging Response Rates in Patients ...
- Cyclacel Reports Phase 2 Sapacitabine Data In Acute Myeloid Leukemia And Myelodysplastic Syndromes At 2009 Ash Annual Meeting
- Positive Phase II clinical data for Clavis Pharma's Elacytarabine presented at ASH Annual Meeting
- Drug Shows Promise for T315I-Mutated Chronic Myeloid Leukemia
- AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
- Synta Pharmaceuticals Announces Encouraging Results for Elesclomol in AML In Vitro and Patient Ex-Vivo Studies Presented at ASH
- CytRx Announces Positive Phase 2 Results For Tamibarotene in the Treatment of Relapsed Acute Promyelocytic Leukemia
- ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Multiple Myeloma
- VELCADE (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
- Data from Three Phase II Trials to be Presented at the 51st American Society of Hematology Annual Meeting Demonstrate that INCB18424, a Selective JAK1/JAK2 Inhibitor, Has Potential in Multiple Hematology Conditions
- Allos Therapeutics' FOLOTYN Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
- Phase III Study of Rivaroxaban Shows That Extending Anticoagulant Treatment by Six or 12 Months Significantly Reduced Risk of Second Symptomatic VTE
- Gloucester Pharmaceuticals Presents ISTODAX Data Demonstrating Clinical Benefit in Patients with CTCL Including Blood Involvement at ASH Annual Meeting
- Onconova Therapeutics Announces Presentation of Clinical Proof of Concept of ON 01910.Na in Patients with High Risk Myelodysplastic Syndrome (MDS) at ASH 2009 Annual Meeting
- VELCADE (Bortezomib) for Injection Based Regimens Result in Lower Costs and Less Patient Burden Than Other Commonly Used Multiple Myeloma Treatment Regimens
- Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
- Soliris Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting
- Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
- NanoBio to Present Data on its Novel Nanoemulsion-based Vaccine Adjuvant Platform at the World Influenza Congress
- Soliris Reduced Hemolysis, Lowered Thrombosis Rate and Improved Quality of Life in Patients with PNH Who Had Previously Never Been Transfused
December 8, 2009
- Semafore Pharmaceuticals Reports Encouraging Phase I Data at ASH for Novel PI3K/mTOR Pathway Inhibitor
- New long-term safety and efficacy data build confidence in AED Vimpat; data presented at AES meeting
- Second-line CML Drugs Evoke Faster Response than Front-line Therapy
- Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia
- Study Confirms Novel Mechanism of CeNeRx's Phase 2 Antidepressant Drug
- Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy
- Long-Term Bexxar Data Demonstrate Overall Survival
- EnVivo Pharmaceuticals Announces Results Showing In-Vivo Reduction of Aggregated B-Amyloid
- Antiepileptic Drugs Not Associated With Increased Risk of Suicide Attempts in Patients With Bipolar Disorder
- Novartis Tasigna (nilotinib) Trial Shows Superior Results to Glivec (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
- New Schizophrenia Data Shows Positive Impact on Cognitive Domains
- Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
- The Addition of VELCADE (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients with Non-Hodgkin's Lymphoma
- Memgen's ISF35 Sensitizes Leukemia Cells to Chemotherapy
- Doxorubicin Transdrug: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated in a phase II clinical trial
- The International Myeloma Foundation Says Important Studies May Offer New Approaches to Treating Multiple Myeloma
- MDS Foundation Says That ASH 2009 is the Culmination of a Banner Year for MDS and AML
- Pharmatech Conference Returns to Shanghai to Advise Chinese Firms on SFDA Regulatory Guidelines
- Genzyme's Mozobil Shows Promise in Chemosensitization
- Acceleron Pharma Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at the 51st Annual Meeting of the American Society of Hematology
- VELCADE (Bortezomib) for Injection Based Therapy Delivers Sustained Overall Survival Advantage in Patients with Previously Untreated Multiple Myeloma
- Abraxis Provides Overview of Abraxane Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
- Neovacs Initiates a Phase II Clinical Trial of TNFα Kinoid in Rheumatoid Arthritis Patients Failing TNFα Monoclonal Antibody Therapy
- HemaQuest Pharmaceuticals Presents Promising Results in Sickle Cell Disease and Beta Thalassemia
- Eidogen-Sertanty Licenses TIP to the FDA
- Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
- Silicom Ventures Produces First Annual Personalized Medicine Conference ? PMWC 2010 ? in Silicon Valley
- Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Geron Presents Interim Clinical Data on Its Telomerase Vaccine at the 2009 American Society of Hematology Meeting
- Calistoga Pharmaceuticals' CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
- Gentium Announces Final Clinical Trial Results for Defibrotide Presented at the American Society of Hematology Conference
- The Group Room Features Live Videocast from San Antonio Breast Cancer Symposium
December 9, 2009
- Important Progress in Treatment of Early and Late Stage Breast Cancer With Herceptin, Avastin and T-DM1
- Knopp Neurosciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS
- ASA404 to feature in Novartis Oncology Pipeline Update and at San Antonio Breast Cancer Symposium
- Drug improves quality of life in cancer patients, Clinuvel strengthens filing dossier
- Degarelix (Firmagon) Vs Leuprolide (Lupron Depot) In Patients With Advanced Prostate Cancer: Further Analysis From A Phase IIi Pivotal Trial
- ChemGenex?s Omapro Featured During ASH Oral Session
- Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts
December 10, 2009
- RegeneRx Announces Final Clinical Results from Phase I Trial with RGN-352
- AVANIR Pharmaceuticals Presents Zenvia Phase III Results in Amyotrophic Lateral Sclerosis Patient Cohort at the International Symposium on ALS / MND
- Rituxan (rituximab) is the first treatment to show improved overall survival in previously untreated patients with chronic lymphocytic leukemia
- GAO: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed
- Vascular Pharmaceuticals, PhytoChem Pharmaceuticals To Participate at CED's December STREAK Seminar
- XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference
- Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
- Phase III Study Demonstrates INVEGA SUSTENNA) (paliperidone palmitate) Statistically Similar to RISPERDAL CONSTA (risperidone) Long-Acting Injection
- BioAlliance Pharma: Breakthrough positive phase III results with acyclovir Lauriad Primary and secondary endpoints met ? Final results
- Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
- Pfizer Announces Updated Trial Results for Aromasin (exemestane tablets) In Switch And Upfront Settings
- GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, Albert Einstein College of Medicine, Centers for Disease Control and Prevention and Affinium Pharmaceuticals Explore Advances in Anti-Infective Drug Development
- New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
- NxStage to Present at the 28th Annual J.P. Morgan Healthcare Conference
- Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
- Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium
- 6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
December 11, 2009
- Zevalin (Ibritumomab Tiuxetan) Demonstrated Activity in Several Investigational Phase 2 Trials Presented at the 51st Annual Meeting of the American Society of Hematology
- HHS Science Seminar for Media: Advances in Influenza Vaccine Technologies
- Flu Vaccine Webcast
- Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
- Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential
- Genomic Health Announces Results of Clinical Survey Showing Use of Oncotype DX Changes Treatment Recommendations for Women With Lymph Node-Positive Breast Cancer, Leading to Overall Reduction in Chemotherapy
- Phase III CONFIRM Study Shows Faslodex (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer
- iCo Therapeutics Provides Phase 1 Diabetic Macular Edema (DME) Clinical Trial Update and Phase 2 Trial Guidance
- Delaware Bio Members Showcase Technology/Services and Raise Money for Junior Achievement's Newest Program
December 14, 2009
- 9th Colloque Médecine et Recherche of la Fondation Ipsen in the series Endocrinology: ?Novel Insights in Adipose Cell Functions?
- Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial in prostate cancer patients
- Chelsea Therapeutics Reports Subgroup Analysis of 44 Parkinson's Patients in Study 302 Shows Highly Statistically Significant Benefits of Droxidopa Therapy
- Degarelix (Firmagon®) Vs Leuprolide (Lupron Depot®) In Patients With Advanced Prostate Cancer: Further Analysis From A Phase III Pivotal Trial
- ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
- AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
- GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
- Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies
- Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Women Previously Treated with Chemotherapy for Advanced Breast Cancer
- EpiCept to Present at Lippert/Heilshorn & Associates Life Sciences Virtual Conference
- Weitz & Luxenberg Alerts Pompton Lakes Residents to New Health Report
- Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination with Trastuzumab May Improve Clinical Response Rates in HER2 Positive Patients with Advanced Metastatic Disease
- ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
- Array BioPharma Announces Positive Interim Results for Phase 1 Study of Its HER2 Inhibitor, ARRY-380, in Cancer Patients
- New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors in Women With Highly Advanced HER2-Positive Breast Cancer
- Ipsen Establishes Optimal Biological Dose for BN83495 Steroid Sulphatase (STS) Inhibitor in ER-Positive Metastatic Breast Cancer
- Pfizer Announces Neratinib Data In HER2 Positive Breast Cancer
- ARIAD Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab
- Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
December 15, 2009
- Positive Phase IIb Topline Clinical Data for Celgene Oral Compound Apremilast (CC-10004) Reported for Patients with Moderate-to-Severe Psoriasis
- Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA in DURATION-5 Study
- Pharma announces study results for Kristalose
- Governor Mitt Romney to Deliver Keynote Address at Sixth Annual Armada Specialty Pharmacy Summit in 2010
- Proteostasis Scientific Founders Publish Paper in Cell Establishing Role of the Proteostasis Network in Alzheimer's Disease
- Picarro Introduces Fully Automated and Integrated System for Bulk 13C Analysis
- Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42
December 16, 2009
- Achillion Announces Positive Preliminary Phase 1b Proof of Concept Data With ACH-1625 to Treat Hepatitis C
- Breakthrough in treatment of Traumatic Brain Injury: KeyNeurotek's clinical study reaches primary endpoint and shows significant increase in survival
- Intercell provides update on ongoing Phase II vaccine studies
- Drug for Alzheimer Disease Does Not Appear to Slow Cognitive Decline
- Camargo Presents at the International Conference of the Korean Society of Pharmaceutical Services and Technology
- Derycz Scientific Signs Distribution Deals With Seven Additional Publishers
- UPDATED TIME: Secretary Sebelius and HHS Senior Officials to Provide an Update and Look Ahead in the Fight Against the 2009 H1N1 Flu
December 17, 2009
- BioDelivery Sciences Announces Positive Phase 2 Pain Trial Results for BEMA Buprenorphine
- Ipsen's Partner Roche Announces that Taspoglutide Meets its Primary Endpoints in Two Further Head-to-head Phase III Studies with Insulin Glargine (Lantus) and versus Placebo in Patients with High Body Mass Index (BMI)
- Cardium Reports on Recent Norwegian Study Revealing That History of Foot...
- AM-Pharma announces positive results from its Acute Kidney Injury trial
- Ipsen?s partner Roche announces that Taspoglutide meets its primary endpoints in two further head-to-head phase III studies with insulin glargine (Lantus) and versus placebo in patients with high body mass index (BMI)
- DURECT Reports Positive Phase IIb Data from POSIDUR Clinical Program
- ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
- Published in "Bone" Journal, Scientific Researches Confirm Peptan Hydrolyzed Collagen Benefits on Bone Health
- Unigene Announces Promising Preclinical Results in Its Obesity Peptide Program
- Toviaz 8 Mg Was More Effective Than Detrol LA In Treating Urge Urinary Incontinence In Patients With Overactive Bladder
- New Study Published in JAMA Supports Neurotez Plans for the Development of Leptin as a Therapy for AD
December 18, 2009
- Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
- Lung Cancer Alliance Disappointed With Food and Drug Administration Committee Recommendation
- Initial Data from CALGB-Led Study of Treatment with Continuous REVLIMID in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Reported
- Clinuvel announces PLE Phase III preliminary results
- More Good News for Myeloma Patients Could Change Patterns of Treatment
- BioSquare 2010 ? International players of the biotechnology and pharma sectors will meet in Geneva from 1 to 2 February 2010 alongside decision makers and several delegations.
- Drug For Multiple Myeloma Demonstrated To Significantly Extend Disease-Free Survival
December 21, 2009
- Meta-Analysis of Independent Research Supports Potential for Oral Salmon Calcitonin Using Emisphere's Eligen Technology as Therapeutic Option for Persistent Musculoskeletal Pain
- Idera Pharmaceuticals Announces Positive Interim Data from Phase 1 Clinical Trial of IMO-2125 in Chronic Hepatitis C Patients
- Findings of Australian Trial of CSL's Pandemic (H1N1) 2009 ?Swine' Flu Vaccine in Children Published in Journal of the American Medical Association (JAMA)
- Actelion Pharmaceuticals Ltd (EN) - Investigational dual orexin receptor antagonist almorexant meets primary endpoint in two-week phase III study in patients suffering from primary insomnia
- Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp
- Positive Results for LEO Pharma's Phase III Actinic (Solar) Keratosis Trials on the Face and Scalp
- Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
- Firmagon has a Significantly Greater Probability of PSA Recurrence-Free Survival Than Leuprolide in Prostate Cancer Patients
- Medicago reports positive Phase I results for its avian flu pandemic vaccine
December 22, 2009
- Ablynx Demonstrates Proof-of-Concept by Biomarker For Its Anti-Thrombotic ALX-0081
- Quadrant HealthCom Inc. Announces the Purchase of Dowden Professional Publications
December 23, 2009
- pSivida Announces Positive Results from the Two Phase 3 FAME Trials of Iluvien in Patients with Diabetic Macular Edema
- Lung Cancer Alliance Disappointed With Food and Drug Administration Committee Recommendation
December 28, 2009
- Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax, Its Vaccine Against Ricin Toxin
- Study Redefines Placebo Effect as Part of Effective Treatment
- Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
December 29, 2009
- Alimera Announces Positive Results From the Two Phase 3 FAME Trials of Iluvien in Patients With Diabetic Macular Edema
- Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
- MJFF Funds Two Investigations of Placebo Effect in Parkinson's Disease
